Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

Clinical pharmacology and therapeutics - 1 Jun 2006

Schalekamp Tom, Boink Gerard J J, Visser Loes E, Stricker Bruno H Ch, de Boer Anthonius, Klungel Olaf H

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Blood Coagulation Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Cytochrome P-450 CYP2C9

Share to International Normalized Ratio

Share to Netherlands

Source

Identifiers

PMID: 16765138
DOI: 10.1016/j.clpt.2006.03.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?PMID 16765138Read ↗

Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.Semantic proximity Read ↗

A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.Semantic proximity Read ↗

The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.Semantic proximity Read ↗

A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism.Semantic proximity Read ↗

Pharmacogenetics and coumarin dosing--recalibrating expectations.Semantic proximity Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.Semantic proximity Read ↗

Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.Semantic proximity Read ↗

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.Semantic proximity Read ↗

Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? Yes.Semantic proximity Read ↗

Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.Semantic proximity Read ↗

Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.